Hemostemix (TSE:HEM) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hemostemix Inc. has entered into a manufacturing partnership with CytoImmune Therapeutics to produce ACP-01, a cell therapy for severe arterial diseases, in a cutting-edge facility in Puerto Rico. Additionally, Hemostemix has secured $1.8 million in financing, with CytoImmune investing $1.37 million, signifying a strong commitment to the advancement of cell therapy. This strategic move aims to increase production and sales, offering a lifeline to patients facing chronic pain and potential limb amputation.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue